Effect of Combination Therapy with Atorvastatin and Ursodeoxycholic Acid on the Course of Ischemic Heart Disease with Co-Existent Non-Alcoholic Fatty Liver Disease and Obesity
Non-alcoholic fatty liver disease is considered as an independent predictor of cardiovascular diseases which plays an important role in the development of ischemic heart disease. The drug most frequently used for treating this comorbidity is atorvastatin which favours better survival outcomes and is...
Saved in:
Main Author: | Karpyshyn, Nataliya (Author) |
---|---|
Format: | EJournal Article |
Published: |
Ivano-Frankivsk National Medical University,
2016-12-12.
|
Subjects: | |
Online Access: | Get Fulltext Get Fulltext |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Quality of Life of Patients with Stable Coronary Artery Disease Combined with Non-Alcoholic Fatty Liver Disease
by: Vakalyuk, Iryna, et al.
Published: (2016) -
Non-Alcoholic Fatty Liver Disease Research 2016
by: Amedeo Lonardo (Ed.)
Published: (2018) -
Nutritional Intake and the Risk for Non-alcoholic Fatty Liver Disease (NAFLD)
by: Jörn M. Schattenheim (Ed.)
Published: (2019) -
Non-Alcoholic Fatty Liver Disease - Molecular Bases, Prevention and Treatment
by: Rodrigo Valenzuela
Published: (2018) -
Ischemic Heart Disease
Published: (2013)